tert-butyl 2-(pyridin-3-yl)-4-(tosyloxy)-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate | 1310064-24-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: tert-butyl 2-(pyridin-3-yl)-4-(tosyloxy)-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate
• CAS: 1310064-24-4
• 化学式: C₂₄H₂₆N₄O₅S
• 分子量: 482.56
• InChiKey: UMQIUXOVOKXMDI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.91
• 重原子数：
  34.0
• 可旋转键数：
  4.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  111.58
• 氢给体数：
  0.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  tert-butyl 2-(pyridin-3-yl)-4-(tosyloxy)-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate 、 2-甲基苯硼酸 在 potassium phosphate 、 palladium diacetate 、 2-(二环己基膦基)联苯 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以89%的产率得到
  参考文献：
  名称：

  Synthesis and SAR of pyrimidine-based, non-nucleotide P2Y14 receptor antagonists

  摘要：

  A weak antagonist of the pyrimidinergic receptor P2Y(14) containing a dihydropyridopyrimidine core was identified through high-throughput screening. Subsequent optimization led to potent, non-UTP competitive antagonists and represent the first reported non-nucleotide antagonists of this receptor. Compound 18q was identified as a 10 nM P2Y(14) antagonist with good oral bioavailability and provided sufficient exposure in mice to be used as a tool for future in vivo studies. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.084
• 作为产物：
  描述：

  3-甲脒基吡啶盐酸盐 在 4-二甲氨基吡啶 、 potassium carbonate 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 20.0h， 生成 tert-butyl 2-(pyridin-3-yl)-4-(tosyloxy)-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate
  参考文献：
  名称：

  Synthesis and SAR of pyrimidine-based, non-nucleotide P2Y14 receptor antagonists

  摘要：

  A weak antagonist of the pyrimidinergic receptor P2Y(14) containing a dihydropyridopyrimidine core was identified through high-throughput screening. Subsequent optimization led to potent, non-UTP competitive antagonists and represent the first reported non-nucleotide antagonists of this receptor. Compound 18q was identified as a 10 nM P2Y(14) antagonist with good oral bioavailability and provided sufficient exposure in mice to be used as a tool for future in vivo studies. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.084